Literature DB >> 11999235

Will Australian men use male hormonal contraception? A survey of a postpartum population.

Gareth C Weston1, Michelle L Schlipalius, Meabh Ni Bhuinneain, Beverley J Vollenhoven.   

Abstract

AIM: To survey the attitudes of a population of Australian men to potential use of male hormonal contraception (MHC).
DESIGN: Survey of male partners of women who had recently given birth. Men were approached while visiting their female partners on the ward. PARTICIPANTS: 118 out of 148 Australian-born English-speaking men who were approached.
SETTING: Postnatal ward of Monash Medical Centre (a public teaching hospital in Melbourne), between October 2000 and April 2001. MAIN OUTCOME MEASURE: Attitudes towards potential use of MHC, rated on a five-point scale.
RESULTS: 89/118 men surveyed (75.4%; 95% Cl, 67.7%-83.2%) indicated that they would consider trying MHC if it were available. The three most popular choices for method of administration of MHC were (in descending order) an oral pill, a three-monthly injection, or a two-yearly injection. A statistically significant association was found between acceptability of vasectomy and acceptability of MHC (70.5% of men who indicated they would try MHC [MHC "triers"] found vasectomy acceptable versus 44.5% of MHC "non-triers"; P = 0.011). Triers reported a higher rate of approval of MHC by their female partners than non-triers (79.8% v 13.8%, respectively; P < 0.0001).
CONCLUSIONS: MHC appears to be acceptable to a majority of Australian men when surveyed in a postpartum context. Attitudes of men towards existing male contraception, as well as the attitudes of their partners, appear to exert a strong influence on acceptability of MHC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11999235     DOI: 10.5694/j.1326-5377.2002.tb04374.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  6 in total

1.  Exploring older adolescents' and young adults' attitudes regarding male hormonal contraception: applications for clinical practice.

Authors:  Arik V Marcell; Keith Plowden; Shameeka M Bowman
Journal:  Hum Reprod       Date:  2005-07-08       Impact factor: 6.918

Review 2.  Recent methodological advances in male hormonal contraception.

Authors:  Peter Y Liu; Ronald S Swerdloff; Christina Wang
Journal:  Contraception       Date:  2010-05-21       Impact factor: 3.375

Review 3.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

4.  Pharmacokinetics and pharmacodynamics of oral testosterone enanthate plus dutasteride for 4 weeks in normal men: implications for male hormonal contraception.

Authors:  John K Amory; Thomas F Kalhorn; Stephanie T Page
Journal:  J Androl       Date:  2007-11-28

Review 5.  Male hormonal contraception: hope and promise.

Authors:  Katarzyna Piotrowska; Christina Wang; Ronald S Swerdloff; Peter Y Liu
Journal:  Lancet Diabetes Endocrinol       Date:  2016-02-23       Impact factor: 44.867

6.  Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in Men.

Authors:  Sherry Wu; Fiona Yuen; Ronald S Swerdloff; Youngju Pak; Arthi Thirumalai; Peter Y Liu; John K Amory; Feng Bai; Laura Hull; Diana L Blithe; Bradley D Anawalt; Toufan Parman; Kyuri Kim; Min S Lee; William J Bremner; Stephanie T Page; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2019-03-01       Impact factor: 6.134

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.